<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>By using the GRADE system, we updated the guidelines for management of follicular cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> issued in 2006 from SIE, SIES, and GITMO group </plain></SENT>
<SENT sid="1" pm="."><plain>We confirmed our recommendation to frontline chemoimmunotherapy in patients with Stage III-IV disease and/or high <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> burden </plain></SENT>
<SENT sid="2" pm="."><plain>Maintenance rituximab was also recommended in responding patients </plain></SENT>
<SENT sid="3" pm="."><plain>In patients relapsing after an interval longer than 12 months from frontline therapy, we recommended chemoimmunotherapy with non cross-resistant regimens followed by rituximab maintenance </plain></SENT>
<SENT sid="4" pm="."><plain>High dose chemotherapy followed by hematopoietic stem cell transplant was recommended for young fit patients who achieve a response after salvage chemoimmunotherapy </plain></SENT>
</text></document>